In 2022, a study published by Nakagawa et al. found that targeting the EGF receptor in conjunction with anti-VEGF medication results in improved survival rates in lung cancer patients, pinpointing the potential advantage of targeting several pro-angiogenic pathways [48]. The gene discussed is VEGFA; the disease is lung cancer.